Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can cosentyx impact flu shot's protective effects?How does aspirin's safety profile differ from advil during long term use?Can you provide a breakdown of yervoy's discounted cost?How does keytruda's patent impact your work?What is kymriah's duration in patient's system?
See the DrugPatentWatch profile for ruxolitinib
According to DrugPatentWatch.com, Apotex's Ruxolitinib ANDA filing in the US was submitted on March 18, 2021 [1]. Ruxolitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of myelofibrosis [2]. Apotex is a Canadian pharmaceutical company that develops and manufactures generic versions of brand-name drugs, filing Abbreviated New Drug Applications (ANDAs) to gain FDA approval for generic versions of these products. It's worth noting that the FDA's approval or rejection of this ANDA filing is not publicly known at this time. Sources: [1] DrugPatentWatch.com [2] Wikipedia: Ruxolitinib
Other Questions About Ruxolitinib :